R788 disodium hexahydrate (BioDeep_00000858912)
代谢物信息卡片
R788 disodium hexahydrate
化学式: C23H36FN6Na2O15P (732.1755608)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1(C(=O)N(C2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)COP(=O)([O-])[O-])C.O.O.O.O.O.O.[Na+].[Na+]
InChI: /p-2
描述信息
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- P Zhu, N Cui, Z-Y Song, W-X Yong, X-X Luo, G-C Wang, X Wang, Y-N Wu, Q Xu, L-M Zhang, G-X Hao, Y Liu, Z-M Zhang. PRC1 plays an important role in lung adenocarcinoma and is potentially targeted by fostamatinib.
European review for medical and pharmacological sciences.
2022 12; 26(23):8924-8934. doi:
10.26355/eurrev_202212_30567. [PMID: 36524512] - Ryosuke Matsukane, Kimitaka Suetsugu, Takeshi Hirota, Ichiro Ieiri. Clinical Pharmacokinetics and Pharmacodynamics of Fostamatinib and Its Active Moiety R406.
Clinical pharmacokinetics.
2022 07; 61(7):955-972. doi:
10.1007/s40262-022-01135-0. [PMID: 35781630] - Sovan Saha, Anup Kumar Halder, Soumyendu Sekhar Bandyopadhyay, Piyali Chatterjee, Mita Nasipuri, Debdas Bose, Subhadip Basu. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?.
Methods (San Diego, Calif.).
2022 07; 203(?):564-574. doi:
10.1016/j.ymeth.2021.08.007. [PMID: 34455072] - Maan H Harbi, Christopher W Smith, Fawaz O Alenazy, Phillip L R Nicolson, Alok Tiwari, Steve P Watson, Mark R Thomas. Antithrombotic Effects of Fostamatinib in Combination with Conventional Antiplatelet Drugs.
International journal of molecular sciences.
2022 Jun; 23(13):. doi:
10.3390/ijms23136982. [PMID: 35805988] - David J Kuter, Kerry A Rogers, Michael A Boxer, Michael Choi, Richy Agajanian, Donald M Arnold, Catherine M Broome, Joshua J Field, Irina Murakhovskaya, Robert Numerof, Sandra Tong. Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-label study.
American journal of hematology.
2022 06; 97(6):691-699. doi:
10.1002/ajh.26508. [PMID: 35179251] - Sokratis A Apostolidis, Amrita Sarkar, Heather M Giannini, Rishi R Goel, Divij Mathew, Aae Suzuki, Amy E Baxter, Allison R Greenplate, Cécile Alanio, Mohamed Abdel-Hakeem, Derek A Oldridge, Josephine R Giles, Jennifer E Wu, Zeyu Chen, Yinghui Jane Huang, Jonathan Belman, Ajinkya Pattekar, Sasikanth Manne, Oliva Kuthuru, Jeanette Dougherty, Brittany Weiderhold, Ariel R Weisman, Caroline A G Ittner, Sigrid Gouma, Debora Dunbar, Ian Frank, Alexander C Huang, Laura A Vella, John P Reilly, Scott E Hensley, Lubica Rauova, Liang Zhao, Nuala J Meyer, Mortimer Poncz, Charles S Abrams, E John Wherry. Signaling Through FcγRIIA and the C5a-C5aR Pathway Mediate Platelet Hyperactivation in COVID-19.
Frontiers in immunology.
2022; 13(?):834988. doi:
10.3389/fimmu.2022.834988. [PMID: 35309299] - Bibian M E Tullemans, Alicia Veninga, Delia I Fernandez, Maureen J B Aarts, Johannes A Eble, Paola E J van der Meijden, Johan W M Heemskerk, Marijke J E Kuijpers. Multiparameter Evaluation of the Platelet-Inhibitory Effects of Tyrosine Kinase Inhibitors Used for Cancer Treatment.
International journal of molecular sciences.
2021 Oct; 22(20):. doi:
10.3390/ijms222011199. [PMID: 34681859] - Santino Caserta, Anna Maria Zaccuri, Vanessa Innao, Caterina Musolino, Alessandro Allegra. Immune thrombocytopenia: options and new perspectives.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
2021 Oct; 32(7):427-433. doi:
10.1097/mbc.0000000000001058. [PMID: 34224465] - Essam Ezzeldin, Muzaffar Iqbal, Yousif A Asiri, Ahmed Y A Sayed, Rashad Alsalahi. Eco-Friendly UPLC-MS/MS Method for Determination of a Fostamatinib Metabolite, Tamatinib, in Plasma: Pharmacokinetic Application in Rats.
Molecules (Basel, Switzerland).
2021 Jul; 26(15):. doi:
10.3390/molecules26154663. [PMID: 34361816] - Nikhil Vergis, Rachel Phillips, Victoria Cornelius, Alexia Katsarou, Taryn Youngstein, Lucy Cook, Michelle Willicombe, Clio Pilay, Tina Shturova, Melanie Almonte, Asad Charania, Richard Turner, Onn Min Kon, Graham Cooke, Mark Thursz, Svetlana Cherlin, James Wason, Dragana Milojkovic, Andew J Innes, Nichola Cooper. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
Trials.
2021 Apr; 22(1):270. doi:
10.1186/s13063-021-05190-z. [PMID: 33845867] - Jeffrey R Strich, Marcos J Ramos-Benitez, Davide Randazzo, Sydney R Stein, Ashley Babyak, Richard T Davey, Anthony F Suffredini, Richard W Childs, Daniel S Chertow. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.
The Journal of infectious diseases.
2021 03; 223(6):981-984. doi:
10.1093/infdis/jiaa789. [PMID: 33367731] - Neha Tabassum, Hua Zhang, Justin Stebbing. Repurposing Fostamatinib to Combat SARS-CoV-2-Induced Acute Lung Injury.
Cell reports. Medicine.
2020 11; 1(8):100145. doi:
10.1016/j.xcrm.2020.100145. [PMID: 33225317] - Daojun Hu, Boke Zhang, Miao Yu, Wenjie Shi, Li Zhang. Identification of prognostic biomarkers and drug target prediction for colon cancer according to a competitive endogenous RNA network.
Molecular medicine reports.
2020 08; 22(2):620-632. doi:
10.3892/mmr.2020.11171. [PMID: 32468035] - Jiraphorn Issara-Amphorn, Wiwat Chancharoenthana, Peerapat Visitchanakun, Asada Leelahavanichkul. Syk Inhibitor Attenuates Polymicrobial Sepsis in FcgRIIb-Deficient Lupus Mouse Model, the Impact of Lupus Characteristics in Sepsis.
Journal of innate immunity.
2020; 12(6):461-479. doi:
10.1159/000509111. [PMID: 32927460] - Stephen McAdoo, Frederick W K Tam. Role of the Spleen Tyrosine Kinase Pathway in Driving Inflammation in IgA Nephropathy.
Seminars in nephrology.
2018 09; 38(5):496-503. doi:
10.1016/j.semnephrol.2018.05.019. [PMID: 30177021] - Cecilie F Kjelgaard-Petersen, Adam Platt, Martin Braddock, Martin A Jenkins, Kishwar Musa, Emma Graham, Thorbjørn Gantzel, Gillian Slynn, Michael E Weinblatt, Morten A Karsdal, Christian S Thudium, Anne-C Bay-Jensen. Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis.
Arthritis & rheumatology (Hoboken, N.J.).
2018 09; 70(9):1419-1428. doi:
10.1002/art.40527. [PMID: 29669391] - Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey, Dominic Surry, David Sweeny, David Lau, Philip Leese. Effects of Fostamatinib on the Pharmacokinetics of the CYP2C8 Substrate Pioglitazone: Results From In Vitro and Phase 1 Clinical Studies.
Clinical pharmacology in drug development.
2016 May; 5(3):170-9. doi:
10.1002/cpdd.243. [PMID: 27163495] - Robert Elsby, Paul Martin, Dominic Surry, Pradeep Sharma, Katherine Fenner. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Drug metabolism and disposition: the biological fate of chemicals.
2016 Mar; 44(3):398-408. doi:
10.1124/dmd.115.066795. [PMID: 26700956] - P Martin, M Gillen, J Ritter, D Mathews, C Brealey, D Surry, S Oliver, V Holmes, P Severin, R Elsby. Effects of Fostamatinib on the Pharmacokinetics of Oral Contraceptive, Warfarin, and the Statins Rosuvastatin and Simvastatin: Results From Phase I Clinical Studies.
Drugs in R&D.
2016 Mar; 16(1):93-107. doi:
10.1007/s40268-015-0120-x. [PMID: 26748647] - Paul Martin, S Y Amy Cheung, Mark Yen, David Han, Michael Gillen. Characterization of the disposition of fostamatinib in Japanese subjects including pharmacokinetic assessment in dry blood spots: results from two phase I clinical studies.
European journal of clinical pharmacology.
2016 Jan; 72(1):61-71. doi:
10.1007/s00228-015-1961-5. [PMID: 26490353] - Paul Martin, Michael Gillen, David Millson, Stuart Oliver, Clive Brealey, Robert Elsby, Muhammad Baluom, David Lau, Tim Mant. Effects of Fostamatinib on the Pharmacokinetics of Digoxin (a P-Glycoprotein Substrate): Results From in Vitro and Phase I Clinical Studies.
Clinical therapeutics.
2015 Dec; 37(12):2811-22. doi:
10.1016/j.clinthera.2015.09.018. [PMID: 26514315] - Paul Martin, Stuart Oliver, Michael Gillen, Thomas Marbury, David Millson. Pharmacokinetic Properties of Fostamatinib in Patients With Renal or Hepatic Impairment: Results From 2 Phase I Clinical Studies.
Clinical therapeutics.
2015 Dec; 37(12):2823-36. doi:
10.1016/j.clinthera.2015.09.016. [PMID: 26519231] - Omer Nuri Pamuk, Guray Can, Suleyman Ayvaz, Turan Karaca, Gulsum Emel Pamuk, Selim Demirtas, George C Tsokos. Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.
Clinical and experimental rheumatology.
2015 Jul; 33(4 Suppl 91):S15-22. doi:
NULL. [PMID: 26148346] - John Maringwa, Matts Kågedal, Ulrika Wählby Hamrén, Paul Martin, Eugène Cox, Bengt Hamrén. Pharmacokinetic-pharmacodynamic modeling of fostamatinib efficacy on ACR20 to support dose selection in patients with rheumatoid arthritis (RA).
Journal of clinical pharmacology.
2015 Mar; 55(3):328-35. doi:
10.1002/jcph.406. [PMID: 25280085] - M Skinner, K Philp, D Lengel, L Coverley, E Lamm Bergström, P Glaves, H Musgrove, H Prior, M Braddock, R Huby, J O Curwen, P Duffy, A R Harmer. The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation.
British journal of pharmacology.
2014 May; 171(9):2308-20. doi:
10.1111/bph.12559. [PMID: 24329544] - Eva Wex, Eva Thaler, Sylvia Blum, David Lamb. A novel model of IgE-mediated passive pulmonary anaphylaxis in rats.
PloS one.
2014; 9(12):e116166. doi:
10.1371/journal.pone.0116166. [PMID: 25541997] - Sook Ryun Park, Giovanna Speranza, Richard Piekarz, John J Wright, Robert J Kinders, Lihua Wang, Thomas Pfister, Jane B Trepel, Min-Jung Lee, Sylvia Alarcon, Seth M Steinberg, Jerry Collins, James H Doroshow, Shivaani Kummar. A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas.
Cancer chemotherapy and pharmacology.
2013 Apr; 71(4):981-90. doi:
10.1007/s00280-013-2091-3. [PMID: 23404627] - Roy Fleischmann. Novel small-molecular therapeutics for rheumatoid arthritis.
Current opinion in rheumatology.
2012 May; 24(3):335-41. doi:
10.1097/bor.0b013e32835190ef. [PMID: 22357358] - Muhammad Baluom, Emil Samara, Elliott B Grossbard, David T-W Lau. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis.
Journal of clinical pharmacology.
2011 Sep; 51(9):1310-8. doi:
10.1177/0091270010381496. [PMID: 21209239] - David J Sweeny, Weiqun Li, Jeffrey Clough, Somasekhar Bhamidipati, Rajinder Singh, Gary Park, Muhammad Baluom, Elliott Grossbard, David T-W Lau. Metabolism of fostamatinib, the oral methylene phosphate prodrug of the spleen tyrosine kinase inhibitor R406 in humans: contribution of hepatic and gut bacterial processes to the overall biotransformation.
Drug metabolism and disposition: the biological fate of chemicals.
2010 Jul; 38(7):1166-76. doi:
10.1124/dmd.110.032151. [PMID: 20371637] - Guo-Min Deng, Lena Liu, Frances Rena Bahjat, Polly R Pine, George C Tsokos. Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.
Arthritis and rheumatism.
2010 Jul; 62(7):2086-92. doi:
10.1002/art.27452. [PMID: 20222110] - D J Sweeny, W Li, E Grossbard, D T W Lau. Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey.
Xenobiotica; the fate of foreign compounds in biological systems.
2010 Jun; 40(6):415-23. doi:
10.3109/00498251003734244. [PMID: 20415544] - Jennifer Smith, John P McDaid, Gurjeet Bhangal, Ratana Chawanasuntorapoj, Esteban S Masuda, H Terence Cook, Charles D Pusey, Frederick W K Tam. A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis.
Journal of the American Society of Nephrology : JASN.
2010 Feb; 21(2):231-6. doi:
10.1681/asn.2009030263. [PMID: 19959716] - Frances Rena Bahjat, Polly R Pine, Andrea Reitsma, Gail Cassafer, Muhammad Baluom, Sunny Grillo, Betty Chang, Fei Fei Zhao, Donald G Payan, Elliott B Grossbard, David I Daikh. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Arthritis and rheumatism.
2008 May; 58(5):1433-44. doi:
10.1002/art.23428. [PMID: 18438845] - Polly R Pine, Betty Chang, Nathan Schoettler, Mona L Banquerigo, Su Wang, Angela Lau, Feifei Zhao, Elliott B Grossbard, Donald G Payan, Ernest Brahn. Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.
Clinical immunology (Orlando, Fla.).
2007 Sep; 124(3):244-57. doi:
10.1016/j.clim.2007.03.543. [PMID: 17537677]